{"title":"[Efficacy of Arnica in varicose vein surgery: results of a randomized, double-blind, placebo-controlled pilot study].","authors":"M Wolf, C Tamaschke, W Mayer, M Heger","doi":"10.1159/000074778","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In homeopathy ARNICA is widely used as a woundhealing medication and for the treatment of hematomas.</p><p><strong>Objective: </strong>In this pilot study the efficacy and safety of ARNICA D12 in patients following varicose vein surgery were investigated.</p><p><strong>Design: </strong>Prospective, randomized, double-blind, placebo-controlled pilot trial according to ICH GCP guidelines.</p><p><strong>Setting: </strong>The study was conducted by a surgeon at the Angiosurgical Clinic, Berlin- Buch.</p><p><strong>Intervention: </strong>After randomized allocation, 60 patients received either ARNICA D12 or placebo. Start of medication occurred the evening before operation with 5 globules. On the operation day one preoperative and hourly postoperative dosages after awakening were given. On days 2-14 of the study 5 globules 3 times a day were given. OUTCOME CRITERIA: Surface (in cm(2) and using a three-point verbal rating scale) and intensity of hematomas induced by operation, complications of wound healing, and intensity of pain (five-point verbal rating scale) as well as efficacy and safety of the study medication were assessed.</p><p><strong>Results: </strong>Hematoma surface was reduced (from day 7 to day 14) under ARNICA by 75.5% and under placebo by 71.5% (p = 0.4726). The comparison of hematoma surface (small, medium, large) using the verbal rating scale yielded a value of p = 0.1260. Pain score decreased by 1.0 +/- 2.2 points under ARNICA and 0.3 +/- 0.8 points under placebo (p = 0.1977). Remission or improvement of pain was observed in 43.3% of patients in the ARNICA group and in 27.6% of patients in the placebo group. Tolerability was rated as very good in all cases.</p><p><strong>Conclusion: </strong>The results of this pilot study showed a trend towards a beneficial effect of ARNICA D12 with regard to reduction of hematoma and pain during the postoperative course. For a statistically significant proof of efficacy of ARNICA D12 in patients following varicose vein surgery a larger sample size is necessary.</p>","PeriodicalId":80278,"journal":{"name":"Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine","volume":"10 5","pages":"242-7"},"PeriodicalIF":0.0000,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000074778","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000074778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14
Abstract
Introduction: In homeopathy ARNICA is widely used as a woundhealing medication and for the treatment of hematomas.
Objective: In this pilot study the efficacy and safety of ARNICA D12 in patients following varicose vein surgery were investigated.
Design: Prospective, randomized, double-blind, placebo-controlled pilot trial according to ICH GCP guidelines.
Setting: The study was conducted by a surgeon at the Angiosurgical Clinic, Berlin- Buch.
Intervention: After randomized allocation, 60 patients received either ARNICA D12 or placebo. Start of medication occurred the evening before operation with 5 globules. On the operation day one preoperative and hourly postoperative dosages after awakening were given. On days 2-14 of the study 5 globules 3 times a day were given. OUTCOME CRITERIA: Surface (in cm(2) and using a three-point verbal rating scale) and intensity of hematomas induced by operation, complications of wound healing, and intensity of pain (five-point verbal rating scale) as well as efficacy and safety of the study medication were assessed.
Results: Hematoma surface was reduced (from day 7 to day 14) under ARNICA by 75.5% and under placebo by 71.5% (p = 0.4726). The comparison of hematoma surface (small, medium, large) using the verbal rating scale yielded a value of p = 0.1260. Pain score decreased by 1.0 +/- 2.2 points under ARNICA and 0.3 +/- 0.8 points under placebo (p = 0.1977). Remission or improvement of pain was observed in 43.3% of patients in the ARNICA group and in 27.6% of patients in the placebo group. Tolerability was rated as very good in all cases.
Conclusion: The results of this pilot study showed a trend towards a beneficial effect of ARNICA D12 with regard to reduction of hematoma and pain during the postoperative course. For a statistically significant proof of efficacy of ARNICA D12 in patients following varicose vein surgery a larger sample size is necessary.